D. de Graaf

发表

Early patient stratification and predictive biomarkers in drug discovery and development: a case study of ulcerative colitis anti-TNF therapy.

David A. Drubin, D. Laifenfeld, N. L. Catlett, 2012, Advances in experimental medicine and biology.

Applying computational modeling to drug discovery and development.

D. Lauffenburger, Neil Kumar, B. Hendriks, 2006, Drug discovery today.

Computational modelling of ErbB family phosphorylation dynamics in response to transforming growth factor alpha and heregulin indicates spatial compartmentation of phosphatase activity.

D. Lauffenburger, J. Burke, B. Hendriks, 2006, Systems biology.

P-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake.

R. Schimke, I. Roninson, D. de Graaf, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis

David A. Drubin, D. Laifenfeld, A. V. Van Hooser, 2015, BMC Medical Genomics.

Company Profile: Selventa, Inc.

A. Levine, D. de Graaf, D. Fryburg, 2012, Personalized medicine.

Human (MDR1) and mouse (mdr1, mdr3) P-glycoproteins can be distinguished by their respective drug resistance profiles and sensitivity to modulators.

I. Roninson, P. Gros, D. de Graaf, 1995, Biochemistry.

Multi-omic biomarkers unlock the potential of diagnostic testing.

D. de Graaf, 2013, MLO: medical laboratory observer.

Cellular imaging predictions of clinical drug-induced liver injury.

Peter V. Henstock, Peter V Henstock, Jeffrey R. Chabot, 2008, Toxicological sciences : an official journal of the Society of Toxicology.

Identification of endoglin as a functional marker that defines long-term repopulating hematopoietic stem cells

E. Lander, T. Golub, S. Monti, 2002, Proceedings of the National Academy of Sciences of the United States of America.

Decreased internalisation of erbB1 mutants in lung cancer is linked with a mechanism conferring sensitivity to gefitinib.

G J Griffiths, D. Lauffenburger, B. Hendriks, 2006, Systems biology.

Systems diagnostics: anticipating the next generation of diagnostic tests based on mechanistic insight into disease.

D. Laifenfeld, D. de Graaf, D. Fryburg, 2014, Drug discovery today.

Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex–mediated immune responses

L. Pearce, A. Bitonti, J. Andersen, 2019, Science Advances.

Isolation of altered-function mutants and genetic suppressor elements of multidrug transporter P-glycoprotein by expression selection from retroviral libraries.

I. Roninson, D. de Graaf, A. Ruth, 1998, Methods in enzymology.

Multiple effects of acetaminophen and p38 inhibitors: Towards pathway toxicology

B. Hendriks, J. Xu, D. de Graaf, 2008, FEBS letters.

Elevated GM-CSF and IL-1beta levels compromise the ability of p38 MAPK inhibitors to modulate TNFalpha levels in the human monocytic/macrophage U937 cell line.

D. Lauffenburger, P. Sorger, B. Hendriks, 2010, Molecular bioSystems.

A network-based approach to quantifying the impact of biologically active substances.

Julia Hoeng, Manuel C Peitsch, Dexter Pratt, 2012, Drug discovery today.

A decade of Systems Biology: where are we and where are we going to?

Manuel C Peitsch, M. Peitsch, D. de Graaf, 2014, Drug discovery today.

Blood-based identification of non-responders to anti-TNF therapy in rheumatoid arthritis

David A. Drubin, D. Laifenfeld, D. de Graaf, 2015, BMC Medical Genomics.

A protein interaction atlas for the nuclear receptors: properties and quality of a hub-based dimerisation network

E. Bornberg-Bauer, S. Oliver, D. Robertson, 2007, BMC Systems Biology.